ArticlePain reports2025
De novo post-COVID-19 chronic pain: a piece of information about risk factor and clinical features.
Article in Pain reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of Nociception and Inflammatory/Tissue Damage Biomarkers in a Post-COVID-19 Animal Model.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: SARS-CoV-2 infection has been linked with chronic pain, leading to disability and affecting quality of life. Single nucleotide polymorphisms in the Mu-opioid receptor gene, which influence pain intensity, perception, and analgesic response, may contribute to chronic pain development. We compared patients with de novo post-COVID-19 pain with individuals with chronic pain due to knee osteoarthritis (OA) and investigated whether opioid receptor Mu 1 ( Methods: Seventy-one post-COVID-19 pain patients, 113 patients with knee OA, and 157 controls without chronic pain were evaluated using physical examinations, pain assessments, and standardized questionnaires addressing quality of life, cognitive function, emotional status, and sociodemographic data. Results: Although chronic pain intensity was similar between the 2 cohorts, de novo post-COVID-19 pain patients reported higher opioid intake, increased pain sensitivity, and more catastrophic thinking. By contrast, patients with knee OA provided clearer descriptions of their pain and exhibited higher levels of depression and cognitive impairment. Musculoskeletal disorders and lower pain pressure threshold were significantly associated with post-COVID-19 pain development. Although the frequencies of Conclusion: De novo post-COVID-19 pain exhibits different clinical features compared with chronic pain conditions, underscoring the need for tailored management and treatment strategies in this postpandemic scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.